Can the choice reaction time be modified after COVID-19 diagnosis? A prospective cohort study.

Abstract

This study aimed to assess CRT in individuals after acute COVID-19 infection over 1 year. We prospectively analyzed 30 individuals (male: 9, female: 21) with mild-moderate functional status after COVID-19 and 30 individuals (male: 8, female: 22) without COVID-19. Cognitive and neuropsychiatric symptoms were evaluated using the Montreal Cognitive Assessment (MoCA) and Hospital Anxiety and Depression Scale (HADS), respectively. CRT (milliseconds) was evaluated by finding the difference between the photodiode signal and the electromyographic (EMG) onset latency of anterior deltoid, brachial biceps, and triceps during the task of reaching a luminous target. CRT was evaluated three times over 1 year after COVID-19: baseline assessment (>4 weeks of COVID-19 diagnosis), between 3 and 6 months, and between 6 and 12 months. The multiple comparison analysis shows CRT reduction of the anterior deltoid in the COVID-19 group at 3-6 (p=0.001) and 6-12 months (p<0.001) compared to the control group. We also observed CRT reduction of the triceps at 6-12 months (p=0.002) and brachial biceps at 0-3 (p<0.001), 3-6 (p<0.001), and 6-12 months (p<0.001) in the COVID-19 compared to the control group. Moderate correlations were observed between MoCA and CRT of the anterior deltoid (r=-0.63; p=0.002) and brachial biceps (r=-0.67; p=0.001) at 6-12 months in the COVID-19 group. There was a reduction in CRT after acute COVID-19 over 1 year. A negative correlation was also observed between MoCA and CRT only from 6 to 12 months after COVID-19 infection.